Tazemetostat

Phase 3

Epizyme, Inc. (EPZM)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Feb '27

EPZMPhase 3

Tazemetostat Phase 3 Est. Readout

Tazemetostat• Diffuse Large B-cell Lymphoma (DLBCL)599

Feb 2027~Confirmed

CT.gov

00%

Feb '27

EPZMPhase 2

Tazemetostat Phase 2 Est. Readout

Tazemetostat• Diffuse Large B-cell Lymphoma (DLBCL)49

Feb 2027~Confirmed

CT.gov

00%

Competitive Landscape

1 competitor in Diffuse Large B-cell Lymphoma (DLBCL)

View Full Landscape

Drug Information

Target Indication

Diffuse Large B-cell Lymphoma (DLBCL)

Clinical Trial

NCT02875548

Last updated: 12/29/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

EPZM

Epizyme, Inc.

Biotechnology•North America•NASDAQ

Related Pipeline

MosunetuzumabPhase 2

Follicular Lymphoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts